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Abstract 
  BACKGROUND: Cardiovascular diseases (CVD) are the most important causes of human 
mortality in the world. Higher intakes of choline and betaine have been shown to be associated 
with lower plasma homocysteine levels (the putative CVD risk factor). This study aimed to 
review the evidence on the association between dietary intakes of choline and betaine and 
traditional/novel CVD risk factors. 
 METHODS:  We searched in PubMed website from 1990 to 2009, with the use of following 
keywords: "dietary choline and betaine, cardiovascular diseases, metabolic syndrome, 
inflammation". The cross-sectional and prospective studies as well as the clinical trials were 
recruited in this investigation. 
 RESULTS: Dietary intakes of “choline”/“choline and betaine” were not significantly associated 
with CVD risk; however, the higher intakes of choline and betaine were associated with higher 
serum concentrations of CRP, IL-6 and TNF-α. Individuals with high plasma choline levels were 
obese and had elevated plasma triglycerides, HDL and non-HDL cholesterol levels; whereas 
high plasma betaine levels were inversely associated with these biochemical markers. Both 
choline and betaine supplementation resulted in increased blood lipid profiles. 
  CONCLUSION: Although dietary intakes of choline and betaine were not significantly 
associated with CVD incidence, the long-term consumption of these nutrients have been shown 
to prevent CVD mortality by decreasing inflammation and other risk factors. 
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Introduction 
Cardiovascular diseases (CVD) are the major cause of 
mortality in the world which has a very high 
prevalence in developed and industrialized countries. 
In Iran also, cardiovascular diseases and its risk 
factors are increasing, so that 75% of people in 
Isfahan at least have one of the risk factors.1 Increase 
in serum levels of inflammatory biomarkers is one of 
the most important risk factors in incidence of 
atherosclerosis and cardiovascular diseases.2 Thus 
today, cardiovascular diseases are known as 
inflammatory diseases.3 Metabolic syndrome also 
consists of a collection of cardiovascular risk factors 
such as abdominal obesity, dyslipidemia, impairment 
in blood glucose homeostasis and hypertension.4 
Studies have shown high level of total homocysteine 
(tHcy) in fasting status as well as after administration 
of oral methionine load (taking 100 mg methionine 
per kilogram of body weight) is an independent risk
 factor  for  CVD.5-13 Furthermore, high level of 
homocysteine is associated with increase in serum 
levels of inflammatory markers14,15 and metabolic 
syndrome components such as increase in TG and 
blood glucose and abdominal obesity.16,17 Therefore, 
one of the nutritional strategies to reduce CVD is to 
lessen serum tHcy levels.18 Choline (vitamin J) is an 
essential nutrient for keeping normal life of the 
human beings.19,20 Adequate intake (AI) of choline 
for females and males over 18 years old has been 
considered as 42 mg/d and 550 mg/d, respectively. 
The tolerable upper intake level (UL) of choline for 
females and males over 18 y is 3500 mg/d.20,21 
Choline is synthesized in the liver by 
phosphatidylethanolamine N-methyltransferase 
(PEMT) enzyme.19,20 Estrogen stimulates the PEMT 
activity22 that is the reason females need lower levels 
of choline than males do.20,21 5-Adenosil 
homocysteine inhibits the activity of this enzyme.20 
Endogenous synthesis of choline alone cannot meet
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 the needs of human; thus, a free-choline diet would 
lead to incidence of choline deficiency symptoms 
and organ dysfunction (including fatty liver, death of 
the muscle or liver cells and etc.).19,23 Therefore, 
dietary intake of choline is necessary. Choline is 
widely found in different types of animal foods (e.g., 
cow liver, chicken liver, eggs, beef, shrimp, salmon 
and etc.) or vegetable sources (e.g. soybean, wheat 
bran, barley bran, large green cabbage, broccoli and 
etc.).24,25 The followings are biological activities of 
choline: phospholipids precursors such as lecithin, 
sphingomyelin and choline plasmalogen,26 
neurotransmitter acetylcholine precursor,26 and 
subsequently effective on improving neurological 
disorders and memory strength,20,27 an important 
source of methyl groups,26,28 VLDL hepatic 
secretion and preventing from fat accumulation in 
the liver,20 a component of platelet-activating 
factor,20,29 blood clots-formation factor,20 gene 
expression regulators,30 apoptosis and cell 
differentiation,20 and finally, betaine synthesis 
precursors.25,29  
 
Table 1. Brief report of studies evaluated the association between choline and betaine with cardiovascular 
diseases risk factors 
Results  Outcome 
variable
Exposure 
variable Duration  Age (y)  Subjects 
(n)  Design  Reference 
Higher intakes of 
choline and betaine 
were associated with 
lower plasma 
homocysteine levels.
Serum 
tHcy levels 
Usual 
choline and 
betaine 
dietary 
intake
-  25-42 
1477 
healthy 
women 
cross-
sectional  
Chiuve et 
al., 2007
50 
Betaine 
supplementation 
decreased fasting and 
postmethionine-
loading plasma tHcy, 
whereas folic acid 
decreased only fasting 
serum tHcy levels.
Fasting and 
postmethio
nine-
loading 
plasma 
tHcy 
Betaine (6 
g) or  folic 
acid (800 
μg) 
supplementa
tion vs. 
placebo 
6 wk  26-58 
36 healthy 
men and 
women 
double-
blind, 
parallel 
clinical 
trial 
Steenge et 
al., 2003
18 
Choline 
supplementation 
lowers fasting as well 
as postmethionine-
loading plasma tHcy 
concentrations. 
Fasting and 
postmethio
nine-
loading 
plasma 
tHcy 
choline 
supplementa
tion (2.6 g 
as 
phosphatidy
lcholine) vs. 
placebo
2 wk for 
each 
period 
50-71  26 healthy 
men 
double-
blind, 
cross-over 
clinical 
trial 
Olthof et 
al., 2005
47 
Dietary choline or 
choline plus betaine 
intake had no 
significant association 
with incidence of 
CVD.
Incident 
coronary 
heart 
disease 
Usual 
choline and 
betaine 
dietary 
intake 
14 years  45-64 
14430 
healthy 
men and 
women 
prospectiv
e  
Bidulescu 
et al., 
2007
52 
Regular dietary intakes 
of folate, betaine and 
choline were not 
associated with CVD 
risk. 
Incident 
cardiovasc
ular 
disease 
Usual 
dietary 
intakes of 
folate, 
betaine and 
choline
97 mo  49-70 
16165 
healthy 
menopaus
al women 
prospectiv
e  
Dalmeijer 
et al., 
2008
49 
High choline-betaine 
intakes were associated 
with considerable 
reduction in serum 
concentrations of 
inflammatory markers.
Concentrat
ions of 
inflammato
ry markers 
Usual 
choline and 
betaine 
dietary 
intake 
-  18-89 
3042 
healthy 
men and 
women 
cross-
sectional  
Detopoulo
u et al., 
2008
54 
Choline and betaine 
were associated in 
opposite directions 
with key components 
of metabolic 
syndrome.
Metabolic 
syndrome 
component
s 
plasma 
concentratio
ns of 
choline and 
betaine 
- 
48-49 
and 71-
74 
7045 
women 
and men 
cross-
sectional 
Konstanti
nova et 
al., 2008
4 
 
www.mui.ac.ir CHOLINE, BETAINE AND CARDIOVASCULAR DISEASES 
80  ARYA Atherosclerosis Journal 2011 (Summer); Volume 7, Issue 2 
Betaine (trimethylglycine) is the combination of 
tetragonal ammonium compound,4 a production of 
choline oxidation in the inner mitochondrial 
membrane.29,31. Liver and kidney are considered as two 
main locations for choline oxidation.20,31,32 Betaine usually 
is found in wheat bran, spinach, barley bran, shrimp, 
wheat bread and etc.24,25 Due to possessing N+ and COO- 
in its molecular structure, betaine has osmolite property 
and it controls the intracellular osmotic pressure similar to 
electrolytes.4,31 One of the other major biological activities 
of betaine is to transfer methyl group in betaine 
homocysteine methyltransferase (BHMT) reaction.31,33 
Homocysteine is located on intersection of two paths of 
amino acid cysteine synthesis and methionine synthesis.34 
Methyl group is resulted from folate or betaine (and/or 
choline which ultimately will become betaine) in reaction 
with converting homocysteine to methionine.18,35 
Methylation through betaine-homocysteine 
methyltransferase is confined to the kidney and liver while 
methionine synthesis is active in all body cells.36 Many 
studies have shown that folic acid supplementation would 
reduce fasting tHcy levels both in healthy individuals37-39 
and in hyperhomocysteinemia people40,41 while it is not 
very successful in controlling homocysteine levels after 
administration of oral methionine load.18,42-44. On the 
contrary, many studies have shown choline 
supplementation (2.6 g/d) and betaine supplementation 
(1.5-6 g/d) would reduce fasting Hcy levels18,45-47 as well as 
administration of oral methionine load18,47 both in healthy 
and hyperhomocysteinemia people. Moreover, there was 
a significant inverse correlation between high dietary 
choline intake48,49 and betaine intake48 with Hcy serum 
levels. Therefore, considering the suggested mechanisms 
and the importance of CVD, the present study aimed to 
review conducted researches on “association of dietary 
choline and betaine and cardiovascular diseases”   
(Table 1). 
Materials and Methods 
In order to review conducted studies on the association 
of dietary choline and betaine intakes and 
cardiovascular diseases, searching in PubMed was used 
during 1990-2009 with the use of the following 
keywords: dietary choline and betaine, cardiovascular 
diseases, metabolic syndrome, and inflammation. 
Totally, 74 titles were reviewed among the articles. The 
cross-sectional and prospective studies as well as the 
clinical trials were recruited in this study. 
 
The association of choline and betaine intakes 
with serum homocysteine levels  
Some of the studies had evaluated the association of 
choline and betaine intakes with serum tHcy levels. 
Chiuve et al. in 2007, in a cross-sectional design studied 
1477 women in the Nurses Health Study.50 In this 
study, the association between choline and betaine 
intakes with tHcy levels was investigated using linear 
regression model. After adjusting the effect of folate 
intake, it was indicated that the highest quintile of 
choline and betaine intake compared to the lowest 
quintile, had been associated with 8% reduction in 
tHcy levels (p value = 0.07). Moreover, the choline 
from glycerophosphocholine and phosphocholine had 
a significant inverse correlation with tHcy levels. This 
inverse correlation in women who received folate < 400 
µg/d was more evident than women who received 
folate  ≥ 400 µg/d (p value for interaction for 
glycerophosphocholine = 0.03), and in average, alcohol 
intake > 15g/d was evident more than low intake or 
lack of intake of alcohol (< 15g/d) (p value for 
interaction for glycerophosphocholine = 0.02 and for 
phosphocholine = 0.04). The strongest dose-
dependent response was seen in women consuming 
low-methyl diet (high alcohol and low folate intake) (p 
value for interaction for glycerophosphocholine = 0.002 
and for phosphocholine = 0.001). Therefore, according 
to the results of this study, it seems that increase in 
total choline and betaine as well as choline intake from 
water-soluble compounds, glycerophosphocholine and 
phosphocholine, were associated with reduction in 
tHcy levels. Besides, homocysteine remethylation 
would be more dependent on the betaine path, when 
methyl group sources were low resulted from 
inadequate folate or high alcohol consumption. 
Steenge et al. also in a double-blind clinical trial on 36 
healthy men and women with no history of CVD, who 
had slight increase in serum homocysteine levels, 
reviewed the effect of daily betaine supplementation (6 
gr) in comparison with folic acid (800 micrograms folic 
acid plus 6 gr placebo) and placebo (6 gr) on fasting 
serum homocysteine levels and after administration of 
oral methionine for 6 weeks.17 Oral methionine 
administration test was done (receiving 100 mg per 
kilogram of the body weight) before and after the six 
weeks of supplementation. Fasting homocysteine levels 
decreased by 1.8 µmol/L in those who received betaine 
supplement (95% CI -3.6, 0.0; P < 0.05) and by 2.7 
µmol/L in those who received folic acid supplement 
(95% CI -4.5, -0.9, P < 0.05) whereas, fasting 
homocysteine levels was increased by 0.5 µmol/L in 
those who received placebo. Furthermore, in 
comparison with placebo, betaine supplementation 
reduced area under the homocysteine-time curve after 
administration of oral methionine load by 221 
µmol.24h/L (95% CI -425, -16, P < 0.05) while folic 
acid supplementation had no effects. Therefore, 
according to the obtained results of this study, it seems 
that betaine can be useful in controlling homocysteine 
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levels after intake of methionine in those who had a 
slight increase in their homocysteine levels. However, 
the effect of betaine on reducing CVD risk has not 
been determined yet, considering its potential in 
sustaining circulating homocysteine concentrations. 
Many other studies have shown that betaine 
supplementation decreases homocysteine 
concentrations.45,46 On the other hand, since choline is 
the betaine synthesized precursor,29,31 some studies 
have discussed the effect of phosphatidylcholine 
supplement (the form of choline in the foods) on 
fasting homocysteine concentration as well as after 
administration of oral methionine load. Olthof et al. in 
2005 in Netherland, in a double-blind, placebo-
controlled, cross-over study reviewed twenty six 50-71 
year-old healthy men.47 These subjects were randomly 
assigned to either the choline group (2.6 g/d choline 
intake as phosphatidylcholine) or the placebo group 
(oil mixture). Treatment duration in each period lasted 
for two weeks. Fatty acids composition and lipid 
content was similar in both treatments. Oral 
methionine administration test was done at the first 
and the last days of each supplementation period. 
Finally, it was indicated that phosphatidylcholine 
supplementation, compared to placebo, was associated 
with 18% reduction of fasting homocysteine serum 
concentrations (-3 µmol/L; 95% CI, -3.9, -2.1 
µmol/L). Moreover, after intake of 1.5 g/day choline 
as phosphatidylcholine at the first day, total 
homocysteine levels was decreased after administration 
of oral methionine load (-4.8 µmol/L; 95% CI, -6.8, -
2.8 µmol/L). Furthermore, phosphatidyl choline 
supplementation for two weeks -in comparison with 
placebo- reduced homocysteine levels after 
administration of oral methionine load to 29% (-9.2 
µmol/L; 95% CI, -11.3, -7.2 µmol/L). Generally, it 
seems that high dose of choline intake as phosphatidyl 
choline supplementation can reduce fasting 
homocysteine levels as well as after administration of 
oral methionine load in healthy males who had slight 
increase in homocysteine serum levels. Provided that 
high concentration of homocysteine is the cause of 
cardiovascular disease, high levels of choline intake 
would lower the risk of CVD. 
 
The association of dietary choline, betaine and 
folate intake with CVD 
Considering the increase of atherosclerosis risk in low 
choline and betaine intake, due to dysfunction in 
homocysteine-methylation pathway and choline’s 
antioxidant properties,51 investigating the association of 
dietary choline and betaine intake and incidence of 
CVD is of high importance. Bidulescu et al. in 2007 in 
the U.S. in a prospective study for 14 years followed up 
14430 two-race 45-64 year-old women and men from 
Atherosclerosis Risk in Communities study (ARIC) 
who had no history of CVD.52 In this study, nutrient 
intake was assessed using food frequency questionnaire 
(FFQ) including 66 food items based on the choline 
and betaine content in common foods database 
composed with the U.S. Department of Agriculture 
(USDA).53 Moreover, they used Cox Regression Model 
to calculate incidence risk of coronary heart disease 
(CHD) and also regression standardized method to 
eliminate the effect of regression errors. One thousand 
seventy two incidences of CHD were seen during 14 
years of follow-up (1987-2002). After adjusting the 
effect of confounding factors (age, sex, education, race, 
diabetes status, menstrual status, total energy intake, 
folate, methionine, B6, cholesterol, saturated fatty acids, 
animal fats, fiber and animal protein), they realized that 
dietary choline or choline plus betaine intake had no 
significant correlation with incidence of CVD [(95% 
CI), HR for the highest quartile of choline intake, and 
choline plus betaine intake in comparison with the 
lowest quartile was 1.09 (0.79-1.50) and 1.14 (0.83-
1.56), respectively]. The researchers of this study came 
to realize that high dietary choline and betaine intake 
did not prevent from incidence of CHD. However, to 
confirm or reject this finding, they emphasized for 
necessity of conducting more studies in other 
communities. Dalmeijer et al.49  in 2008 in the 
Netherland during a prospective study followed-up 
16165 49-70 year-old-menopausal women from the 
European Prospective Study on Cancer and Nutrition 
(EPIC) for 97 months, who had no history of CVD. In 
this study, nutrient intake using FFQ was assessed as 
178 food items. Assessing folate intake was 
implemented using the Netherland’s National food 
table, and choline and betaine intake using USDA food 
table. The incidence of CHD and cerebrovascular 
accident (CVA) had been controlled through the 
Netherland Health Care Information Center. During 
97 follow-up months, 717 incidences of CVD were 
seen (493 cased of CHD and 224 cases of CVA). After 
adjusting the effect of confounding factors, there was 
found no significant association between dietary folate, 
betaine and choline intake with the risk of CVD [(95% 
CI) HR for the highest in comparison with the lowest 
quartile was 1.23 (0.75-2.01) and 0.9 (0.69-1.71) and 
1.04 (0.71-1.53), respectively]. Moreover, in the 
subsample of the study population with 903 subjects, 
high folate and choline intake significantly was 
associated with reduction of tHcy levels. Therefore, 
according to the obtained results of this study, dietary 
choline, betaine and folate intake had no association 
with the risk of CVD in Dutch menopausal women. 
However, the effect of higher doses of dietary choline 
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and betaine intake (e.g., supplementation or 
fortification) has not been identified yet. 
 
The association of dietary choline and betaine 
intakes with serum concentrations of inflammatory 
biomarkers 
Inflammation plays a crucial role in progression of 
atherosclerosis and cardiovascular diseases. The 
concentrations of inflammatory biomarkers increased 
in patients with hyperhomocysteinemia.14 Therefore, 
effort for reducing inflammatory response through 
reducing homocysteine levels can be effective in 
controlling cardiovascular diseases. Detopoulou et al. 54 
in 2008 in a cross-sectional study on 3042 individuals 
(1514 males and 1528 females) from the ATTICA 
study aged 18-89 years, who had no history of CVD, 
evaluated the association between dietary choline and 
betaine intakes and markers of low-grade systemic 
inflammation. After adjusting the effect of medical 
variables, lifestyle and socio-demographic status, they 
realized that in comparison with the lowest tertile   
(< 250 mg/d), the highest tertile of choline intake   
(> 310 mg/d) was associated with 22% reduction of C-
reactive protein (CRP) concentrations (P < 0.05), 26% 
reduction of interleukin-6 (IL-6) concentrations   
(p < 0.05) and 6% reduction of tumor necrosis factor-α 
(TNF-α) concentrations (P < 0.01). Accordingly, the 
highest tertiles of betaine intake (> 350 mg/d) in 
comparison with the lowest tertiles (< 260 mg/d) was 
associated with 10% reduction in Hcy concentrations 
(P < 0.01), 19% reduction in CRP concentrations   
(P < 0.01) and 12% reduction in TNF-α 
concentrations (P < 0.05). Moreover, they realized that 
incidence rate of hypercholesterolemia in those who 
were at the highest tertiles of choline intake 
significantly was lower than those with the lowest 
tertiles (22% vs. 32%) whereas the prevalence of 
hypercholesterolemia in those who had the highest 
tertiles of betaine intake significantly was higher than 
those with the lowest tertiles (32% vs. 24%). Besides, 
in this study, the subjects had been divided into four 
groups of high choline-betaine intakes, high choline 
and low betaine intakes, low choline and high betaine 
intakes and low choline-betaine intakes. The lowest 
levels of Hcy (P = 0.05), TNF-α (P = 0.03) and IL-6 (P 
= 0.09) was seen in those who had high choline-
betaine intakes. Furthermore, CRP levels also had been 
reduced in high choline-betaine intakes; however, CRP 
levels was lower in those who had high choline and 
low betaine intakes (P = 0.04). Therefore, according to 
the obtained results of this study, high choline-betaine 
intakes was associated with considerable reduction in 
serum levels of inflammatory markers; Zeisel55 believed 
that the low prevalence of CVD among people who 
follow Mediterranean diet, might be attributed to the 
presence of high choline-betaine intakes of such a diet. 
However, further studies are required to confirm or 
reject such results. 
 
The association of plasma choline and betaine and 
metabolic syndrome components 
Metabolic syndrome includes a collection of 
cardiovascular risk factors. Studies have shown that 
tHcy levels would increase with some of the metabolic 
syndrome components such as abdominal obesity, 
dyslipidemia, increase in blood glucose and blood 
pressure.16,17 Some studies have been shown that 
betaine supplementation (4-6 g/d) increased total 
cholesterol levels, LDL-C, TG while choline 
supplementation (2.6 g/d) increased TG levels.46,56 
Therefore, according to the association of 
homocysteine and cardiovascular diseases,5,13 and role 
of choline in metabolism of blood lipids20 and betaine 
function as osmolite,31 the present study aimed to 
review the association between choline and betaine 
plasma levels with cardiovascular risk factors including 
metabolic syndrome components. Konstantinova et al. 
4 in 2008 in Norway, during a cross-sectional study, 
investigated the blood sample of 7045 women and men 
with the ages of 48-49 and 71-74 years. The mean 
serum levels of choline and betaine were 9.9 µmol/L 
and 39.5 µmol/L, respectively. Choline and betaine 
serum levels were lower in women than in men and 
also were lower in those at the age of 48-49 years than 
those at 71-74 years (P < 0.0001). Choline serum levels 
had a positive association with serum TG, serum 
glucose, body mass index (BMI), body fat percentage, 
waist circumference, (P < 0.0001 for all the above) and 
physical activity (P < 0.05) and it had a negative 
association with HDL-C (P < 0.05) and cigarette 
smoking (P < 0.0001). While betaine serum levels had 
negative association with non-HDL-C, TG, BMI, body 
fat percentage, waist circumference, systolic and 
diastolic blood pressure (P < 0.0001 for all the above) 
and smoking (P < 0.05), and it had a positive 
association with HDL-C (P < 0.01) and physical 
activity (P < 0.0001). Therefore, the obtained results of 
this study showed that metabolic syndrome profiles are 
associated with high choline and low betaine serum 
levels; i.e. choline and betaine are associated with 
metabolic syndrome components in two diverging 
directions. 
Discussion 
With reviewing studied researches on dietary choline 
and betaine intake and cardiovascular diseases, it can 
be concluded that the dietary choline and betaine 
intake had no significant association with incidence of 
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CVD.49,52 However, more intakes of these substances 
were associated with significant reduction of serum 
inflammatory markers.54 High dietary choline and 
betaine intakes, similar to supplementation, would 
reduce tHcy levels in healthy and 
hyperhomocysteinemia people.45-49 Moreover, choline 
and betaine serum levels are associated with metabolic 
syndrome components in diverging directions.4 Many 
mechanisms have been suggested for the above 
observations; it seems that high choline intake would 
increase expression and activity of betaine-
homocysteine methyltransferase enzyme (BHMT) in 
the liver and kidney; this enzyme, with transferring 
methyl group, would convert homocysteine to 
methionine and would lead to reduction in tHcy 
levels.18,57,58 Choline also is a betaine precursor; that is 
the reason high choline and betaine intake is 
associated with reduction in homocysteine levels.45-47 
The presence of choline in the form of phosphatidyl 
choline is essential for normal secretion of VLDL 
from the liver 20. Therefore, choline intake would lead 
to cholesterol and TG transport from the liver to the 
vessels.46,52,55,59 On the other hand, betaine-
homocysteine methyltransferase enzyme (BHMT), in 
addition to remethylation of homocysteine, would 
cause increase in hepatic synthesis of ApoB mRNA 
and subsequently ApoB synthesis and VLDL 
secretion 60. Therefore, high betaine intake would be 
associated with increase in total cholesterol levels, 
LDL-C and TG 46. Several mechanisms have been 
suggested to justify the association between choline 
and betaine with inflammatory markers serum levels; 
high Hcy levels is associated with concentrations of 
inflammatory markers.14,15 High choline and betaine 
intakes would reduce Hcy levels and consequently 
inflammatory markers concentration.54 On the other 
hand, Rivera et al. announced that choline and betaine 
cause inhibition of macrophages activity and 
reduction of NFk-B61. And since these two factors are 
the causing factors of inflammation, therefore choline 
and betaine intake can reduce inflammatory markers 
serum levels through this mechanism. According to 
suggestions of some other studies,62-64 high choline 
intake and subsequently betaine synthesis in 
mitochondrial membrane would improve 
mitochondrial membrane and followed by protection 
against oxidative stress and inflammation. Moreover, 
based on theories of Kim et al.65 and Grimble,66 other 
metabolites of choline and betaine such as glycine and 
serine also can be used for synthesis of glutathione. 
Furthermore, Detopoulou54 announced that higher 
choline and betaine intake increases S-
adenosylmethionine (SAM) concentrations and 
reduces  S-adenosylhomocysteine (SAH) 
concentrations that the ratio of them regulates the 
majority of methyltransferases activities. Increase in 
SAM inhibits nitric oxide synthesis,66 reduces NFk-B 
production,67 increases synthesis of glutathione,68 
activates synthetase-B cystathionine enzyme and 
subsequently increases synthesis of cysteine and 
glutathione from cystathionine.69 Besides, choline and 
betaine affect the inflammation status through 
methylation of promoter gene areas which regulate 
the levels of inflammatory markers.70 Mitochondrial 
dysfunction in metabolic syndrome caused to decay 
choline dehydrogenase pathway which may be 
explained by the observed association between 
choline and betaine with metabolic syndrome 
components.4,71,72 Furthermore, Loscalzo59 believed 
that the high values of choline and betaine would 
change cells phenotype via increase in methylation 
and consequently causes atherosclerotic plaque 
progression while some other researchers believed 
antioxidant properties of choline can reduce 
inactivation of endothelial and subsequently the risk 
of vascular blockages.51,52 Since high tHcy levels is 
considered as one of the CVD risk factors, we would 
also review the mechanism of effect of Hcy on 
atherosclerosis,73 homocysteine oxidation products 
like active oxygen species have peroxidation property 
which can damage endothelial tissue.73 Moreover, 
homocysteine reduces peroxidase glutathione enzyme 
expression.73 On the other hand, homocysteine 
increases DNA synthesis in vascular smooth muscle 
cells.73 The combination of homocysteine with nitric 
oxide and formation of S-nitrosohomocysteine can 
accumulate platelets and thrombosis.73 Besides, it 
would lead to reduction of biology access of nitric 
oxide.73 Homocysteine also increases the likelihood of 
blood coagulation through increasing the lipoprotein 
to fibrin connection, reduction in protein C activity 
(anti-coagulation) and reduction in anti-thrombin III 
activity.74 It should be noted that the number of 
studies on the dietary intakes of choline and betaine 
were very limited due to inaccessibility to the amount 
of choline and betaine in foods until recent years.24,25 
Cross-sectional design of some of these studies 
confounded the possibility assessment of causality 
relationship.54 Due to inaccessibility to national 
composition tables, international food-composition 
tables have been used in most of the studies.49,54 
Choline and betaine intake range was limited in most 
communities, therefore the difference of intakes have 
not been observable and comparable between the first 
and fourth quartiles.49 Despite the possibility of 
impact of choline and betaine endogenous synthesis 
on the results, none of these studies had controlled 
these factors.54 Stimulating choline endogenous 
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synthesis by estrogen would result in confounding 
results in women before menopausal age.22 Besides, it 
is also possible that dietary choline and betaine 
and/or different compounds with choline have 
different effect on studied factors.3,54 Since wheat 
bran is the main source of betaine, the observed 
useful association with atherosclerosis and 
inflammatory process might have been due to other 
whole wheat compounds.4 Therefore, conducting 
further prospective studies in this area, using national 
food-composition tables, considering the effect of 
endogenous and dietary choline and betaine 
separately, examining the effect of choline and betaine 
supplementation on inflammation and accurate 
controlling of confounding factors such as estrogen, 
fiber and etc. are recommended for future studies.  
Conclusion 
Although dietary intakes of choline and betaine were 
not significantly associated with CVD incidence, the 
long-term consumption of these nutrients have been 
shown to prevent CVD mortality by decreasing 
inflammation and other risk factors. 
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